Abstract
A new detoxication method based the Bioartificial Liver apparatus and the use of human serum albumin (HSA) and porcine hepatocyte cytosol (PHC) is described. The method is based on the interaction of HSA and PHC with the patient’s blood through a semi-permeable membrane. The apparatus consists of a bioreactor, hemodialyzer, and blood line as well as thermoregulation, oxygenation, and procedure safety systems. The PHC and HSA dialyzing media were tested using the Bioartificial Liver apparatus. They appeared to be highly effective and capable of reducing biochemical markers of cytolysis, cholestasis, and endogenous intoxication in patients without any adverse side effects. Thus, the method can be recommended for further clinical tests and introduction into intensive care practice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
